The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Programmed death-ligand 1 (PD-L1) is a target in aggressive cancers.
• The immune landscape and cancer hallmarks of PD-L1+ tumors are not fully understood.
• The role of PD-L1 in determining therapeutic efficacy requires further investigation.

Purpose of the Study:

• To investigate the immune microenvironment and cancer hallmarks associated with PD-L1 expression in human cancers.
• To elucidate the mechanisms underlying PD-L1 heterogeneity and its impact on patient outcomes.
• To identify novel therapeutic strategies targeting PD-L1+ tumors.

Main Methods:

• Analysis of gene expression data from 9769 patients across 32 cancer types.
• Investigating the association between PD-L1, immune signatures (IFN-γ, myeloid responses), and cancer hallmarks.
• Exploring the mechanistic roles of NF-κB and STAT1 signaling pathways.
• Evaluating therapeutic strategies combining immune checkpoint blockade with macrophage depletion or NF-κB inhibition.

Main Results:

• PD-L1 expression signifies pro-inflammatory myeloid responses, not solely IFN-γ.
• Tumor immune landscapes influence PD-L1 heterogeneity, affecting cancer hallmarks and outcomes.
• Macrophage-derived PD-L1+ cells promote survival, angiogenesis, and metastasis, conferring resistance to therapies.
• T cell-derived STAT1 signaling induces PD-L1+ cells susceptible to apoptosis.
• Combined therapy of immune checkpoint blockade with macrophage depletion or NF-κB inhibition achieved significant cancer regression.

Conclusions:

• PD-L1+ tumors have distinct functional features driven by inflammatory cells.
• Targeting macrophage-driven inflammation and NF-κB signaling is a promising strategy to enhance immune checkpoint blockade efficacy.
• Modulating inflammatory cell activity may benefit patients with PD-L1+ cancers.